Study identifier:D133HR00069
ClinicalTrials.gov identifier:NCT07882212
EudraCT identifier:N/A
CTIS identifier:N/A
Prospective, observational, multicenter, and multicohort study of patients with gastric cancer initiating AstraZeneca-developed and approved drugs in Germany GastRic CAnCEr Real-World Evidence Germany (umbrella study)
gastric cancer
-
no
-
All
300
Observational
18 Years - 130 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2026 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions |
|---|